BN-201; small molecule for Neuromyelytis Optica & progressive MS

Home / BN-201; small molecule for Neuromyelytis Optica & progressive MS
BN-201; small molecule for Neuromyelytis Optica & progressive MS
  • Product Overview: First in class SGK agonist for neurodegenerative diseases
  • Primary Indications; Rare diseases of the eye – Neuromyelitis Optica, (NMO) & acute optical neuritis (AON). Orphan conditions
  • Secondary Indications: Multiple Sclerosis, including progressive (SPMS and PPMS)
  • Core differentiator(s):
    • Primary neuroprotective agent which prevents axonal loss and neuronal death in several animal models driven by different mechanisms of damage, including demyelination, inflammation and hypertension;
    • Promotes remyelination
  • Development stage; Phase 1
  • Opportunity: Available for license collaboration and investment; (Series B round in progress)